3-methoxy-pentan-2-one | 855381-26-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-methoxy-pentan-2-one
• 英文别名: 3-Methoxy-pentan-2-on；3-Methoxypentan-2-one
• CAS: 855381-26-9
• 化学式: C₆H₁₂O₂
• 分子量: 116.16
• InChiKey: FTNLCEAONBXWSO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-methoxy-pentan-2-one 、 巯基乙胺 生成 2-(1-Methoxy-propyl)-2-methyl-thiazolidine
  参考文献：
  名称：

  Cram的自由基定律：NH取代的自由基的立体选择性氢抽象反应

  摘要：

  用（TMS）3 SiH自由基还原手性噻唑烷可揭示酮/亚胺的离子反应与带有NHR取代基的氨基烷基自由基的自由基反应之间的立体化学相似性。

  DOI：

  10.1016/s0040-4039(00)73704-x
• 作为产物：
  描述：

  甲基碘化镁 、 2-methoxybutanenitrile 生成 3-methoxy-pentan-2-one
  参考文献：
  名称：

  Synthesis of 1-Methoxypropyl Ketones

  摘要：

  DOI：

  10.1021/ja01174a060

文献信息

• [EN] SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME<br/>[FR] TRIAZOLES AMINO-SUBSTITUÉS ET PROCÉDÉS D'UTILISATION
  申请人：INST DRUG DELIVERY

  公开号：WO2015095701A1

  公开（公告）日：2015-06-25

  Disclosed are novel substituted amino triazoles of Formula (I), and pharmaceutically acceptable salts thereof. The compounds of Formula (I) are inhibitors of Acidic mammalian chitinase (AMCase) and are useful, in a non-limiting example, for treating asthma. Also provided are pharmaceutical compositions containing at least one compound of the present invention, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and at least one pharmaceutically acceptable carrier, solvent, adjuvant or diluent, and methods of using such compounds and/or compositions to treat asthma and/or to monitor asthma treatment.

  公开了化合物的新型替代氨基三唑的结构，其化学式为（I），以及其药学上可接受的盐。化合物的化学式（I）是酸性哺乳动物几丁质酶（AMCase）的抑制剂，并且在非限制性示例中用于治疗哮喘。还提供了含有本发明至少一种化合物或其药学上可接受的盐、水合物或溶剂化合物的药物组合物，以及至少一种药学上可接受的载体、溶剂、辅料或稀释剂，并使用这些化合物和/或组合物来治疗哮喘和/或监测哮喘治疗的方法。
• [EN] SECO MACROLIDE COMPOUNDS<br/>[FR] COMPOSÉS MACROLIDES DE TYPE SECO
  申请人：FIDELTA D O O

  公开号：WO2017194452A1

  公开（公告）日：2017-11-16

  The present invention relates to seco (opened ring) macrolide compounds of formula (I), to the process for preparation thereof, to the use of said seco macrolide compounds as intermediates for preparation of macrolide based macrocycles, to macrolide based macrocycles obtained from said seco macrolide compounds, to the process for preparation of macrolide based macrocycles, to the pharmaceutical compositions comprising macrolide based macrocycles, and to the use of macrolide based macrocycles as therapeutic agents.

  本发明涉及具有式(I)的开环（seco）大环内酯化合物，其制备方法，所述开环大环内酯化合物作为制备基于大环内酯的中间体的用途，从所述开环大环内酯化合物获得的基于大环内酯的大环内酯，制备基于大环内酯的大环内酯的方法，包括基于大环内酯的大环内酯的制药组合物，以及基于大环内酯的大环内酯作为治疗剂的用途。
• Polyhydroxyalkanoic Acid Having Vinyl, Ester, Carboxyl or Sulfonic Acid Group and Producing Method Therefor
  申请人：Kenmoku Takashi

  公开号：US20080064828A1

  公开（公告）日：2008-03-13

  The invention is to provide a novel polyhydroxyalkanoate having a reactive function group within the molecule and a producing method therefor In a polyhydroxyalkanoate containing a unit having a vinyl group in a side chain, such vinyl group is utilized for deriving a polyhydroxyalkanoate comprising a carboxyl group or a unit having an amide group and a sulfonic acid group.

  本发明旨在提供一种新型聚羟基烷酸酯，其分子内具有反应性功能团，并提供其制备方法。在含有侧链中具有乙烯基团的聚羟基烷酸酯中，利用该乙烯基团来获得含有羧基或含有酰胺基和磺酸基的聚羟基烷酸酯。
• Polyhydroxyalkanoic acid having ester, carboxyl or sulfonic acid group and producing method thereor
  申请人：Kenmoku Takashi

  公开号：US20070117937A1

  公开（公告）日：2007-05-24

  The invention is to provide a novel polyhydroxyalkanoate having a reactive functional group within a molecule, a novel polyhydroxyalkanoate having a novel function by a chemical modification of the polyhydroxyalkanoate having the reactive functional group, and a producing method therefor. A polyhydroxyalkanoate containing a unit having a carboxyl group in a side chain is utilized for deriving a polyhydroxyalkanoate containing a unit having an amide group and a sulfonic acid group in the molecule.
• Cardiovascular Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use
  申请人：Garvey David S.

  公开号：US20080306041A1

  公开（公告）日：2008-12-11

  The invention describes compositions and kits comprising at least one cardiovascular compound comprising at least one heterocyclic nitric oxide donor group, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension and (n) treating ophthalmic disorders. The cardiovascular compounds are preferably β-adrenergic antagonists, angiotensin-converting enzyme (ACE) inhibitors, anti-hyperlipidemic compounds, and antithrombotic and vasodilator compounds. The heterocyclic nitric oxide donor groups are preferably furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines.